Azzota C-1009-50mg ABT-263 (Navitoclax) - 50 mg Solid Powder

ABT-263 (Navitoclax) - 50 mg Solid Powder

ABT-263 (Navitoclax) is an orally bioavailable, small-molecule antagonist of a subset of BCl-2 (B-cell leukemia 2) family of proteins with potential antineoplastic activity. ABT-263 selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w and prevents their binding to the apoptotic effectors Bax and Bak proteins, which may trigger apoptosis in tumor cells overexpressing Bcl-2, Bcl-XL, and Bcl-w.

Targets: BCL-2

Synonym: ABT-263; ABT263; ABT 263; Navitoclax

Chemical Name/IUPAC:(R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide SMILES Code: O=C(NS(=O)(C1=CC=C(N[C atH](CCN2CCOCC2)CSC3=CC=CC=C3)C(S(=O)(C(F)(F)F)=O)=C1)=O)C4=CC=C(N5CCN(CC6=C(C7=CC=C(Cl)C=C7)CCC(C)(C)C6)CC5)C=C4

Technical Data

• Product Name: ABT-263 (Navitoclax)
• Chemical Formula: C47H55ClF3N5O6S3
• Moleculer Weight: 974.61
• CAS#: 923564-51-6
• Appearance: Solid powder
• Purity: > 99% by HPLC
• Solubility: Soluble in DMSO
• Storage: Room temperature for months, or -20ºC for 3 years
• Weight - 50mg